Yamsri Supawadee, Sanchaisuriya Kanokwan, Fucharoen Supan, Fucharoen Goonnapa, Jetsrisuparb Arunee, Wiangnon Surapon, Changtrakul Yossombat, Sanchaisuriya Pattara
Graduate School, Khon Kaen University, Khon Kaen, Thailand.
Acta Haematol. 2007;118(2):99-105. doi: 10.1159/000105677. Epub 2007 Jul 18.
We determined the prevalence of the H63D and the IVS5#1G-A HFE mutations in 370 (169 males and 201 females) Thai thalassemia carriers and 201 normal subjects. While no IVS5#1G-A mutation was found, the H63D heterozygosity was identified in 5.5% (11/201) of normal subjects and 7.3% (27/370) of thalassemia carriers. Within the thalassemic group, the medians (ranges) of serum ferritin were 217.5 ng/ml (20.1-424.3) and 169.8 ng/ml (3.9-3,536.0) in male subjects and 30.4 ng/ml (11.9-130.7) and 49.3 ng/ml (0.6-931.0) in female subjects with (HD) and without (HH) H63D mutation, respectively. The proportions of subjects with elevated ferritin were found to be 37.5% (6/16) for HD and 14.0% (18/129) for HH in male and 0% (0/11) for HD and 3.0% (5/164) for HH in female subjects, respectively. Statistical analysis of all the data revealed no significant difference. Among 14 Hb E/beta-thalassemia patients, no difference in hematological data as well as serum ferritin levels was observed between those with (HD) and without (HH) H63D mutation. Therefore, the H63D heterozygosity has no significant effect on the serum ferritin level and screening for this HFE mutation in thalassemic patients is not recommended.
我们测定了370名(169名男性和201名女性)泰国地中海贫血携带者及201名正常受试者中H63D和IVS5#1G-A HFE突变的患病率。虽然未发现IVS5#1G-A突变,但在5.5%(11/201)的正常受试者和7.3%(27/370)的地中海贫血携带者中检测到H63D杂合性。在地中海贫血组中,男性受试者中,有(HD)和无(HH)H63D突变者的血清铁蛋白中位数(范围)分别为217.5 ng/ml(20.1 - 424.3)和169.8 ng/ml(3.9 - 3536.0);女性受试者中,有(HD)和无(HH)H63D突变者的血清铁蛋白中位数(范围)分别为30.4 ng/ml(11.9 - 130.7)和49.3 ng/ml(0.6 - 931.0)。男性受试者中,HD组铁蛋白升高者比例为37.5%(6/16),HH组为14.0%(18/129);女性受试者中,HD组铁蛋白升高者比例为0%(0/11),HH组为3.0%(5/164)。对所有数据的统计分析显示无显著差异。在14例Hb E/β地中海贫血患者中,有(HD)和无(HH)H63D突变者在血液学数据及血清铁蛋白水平方面均未观察到差异。因此,H63D杂合性对血清铁蛋白水平无显著影响,不建议在地中海贫血患者中筛查该HFE突变。